Reaction Details Report a problem with these data
Target
Galectin-3
Ligand
BDBM468288
Substrate
n/a
Meas. Tech.
Evaluation of Kd Values
Kd
2.00±n/a nM
Citation
Leffler, H; Nilsson, U; Zetterberg, F Hybrid galactoside inhibitor of galectins US Patent US10800804 Publication Date 10/13/2020
More Info.:
Target
Name:
Galectin-3
Synonyms:
LEG3_HUMAN | LGALS3 | MAC2
Type:
Enzyme
Mol. Mass.:
26156.54
Organism:
Homo sapiens (Human)
Description:
P17931
Residue:
250
Sequence:
MADNFSLHDALSGSGNPNPQGWPGAWGNQPAGAGGYPGASYPGAYPGQAPPGAYPGQAPPGAYPGAPGAYPGAPAPGVYPGPPSGPGAYPSSGQPSATGAYPATGPYGAPAGPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI
Inhibitor
Name:
BDBM468288
Synonyms:
3′-Deoxy-3-O-[(5,6-difluoro-2-oxo-3-chromenyl)methyl]-3′-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-1,1′-sulfanediyl-di-β-D-galactopyranoside | US10800804, Example S8b
Type:
Small organic molecule
Emp. Form.:
C30H28F5N3O11S
Mol. Mass.:
733.614
SMILES:
OC[C@H]1OC(S[C@@H]2OC(CO)[C@H](O)[C@@H](C2O)n2cc(nn2)-c2cc(F)c(F)c(F)c2)[C@H](O)C(OCc2cc3c(F)c(F)ccc3oc2=O)C1O |r|